Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure

Nephrol Dial Transplant. 1989;4(5):345-9. doi: 10.1093/oxfordjournals.ndt.a091888.

Abstract

The pharmacokinetic profile of recombinant human erythropoietin (rHuEpo) was studied after a single intravenous dose of 150 U/kg in ten patients with various degrees of renal function: group I, creatinine clearance greater than 80 ml/min, n = 2; group II, creatinine clearance 10-50 ml/min, n = 6; group III, creatinine clearance less than 3 ml/min (patients undergoing haemodialysis) n = 2. Erythropoietin concentrations in serum and urine samples obtained over 48 h were measured by RIA. rHuEpo was cleared from circulation in an exponential fashion, the half-life ranged from 6.5 to 12.7 h (mean 9.03 h) and was not different between the groups. The apparent volume of distribution varied from 0.041 to 0.099 l/kg (mean 0.070 l/kg) this corresponds to 1.5 times the plasma volume and was unrelated to kidney function. Renal clearance (groups I, II) accounted for less than 3% of total body clearance, both parameters were unaffected by decreasing renal function. These results indicate that, in accordance with animal data, the elimination of rHuEpo occurs mainly through non-renal mechanisms.

MeSH terms

  • Adult
  • Aged
  • Dose-Response Relationship, Drug
  • Erythropoietin / administration & dosage
  • Erythropoietin / pharmacokinetics*
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / therapy
  • Kidney Function Tests
  • Male
  • Middle Aged
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacokinetics

Substances

  • Recombinant Proteins
  • Erythropoietin